Next Article in Journal
The Differential Expression of Circular RNAs and the Role of circAFF1 in Lens Epithelial Cells of High-Myopic Cataract
Next Article in Special Issue
The Dark Side of Ultrasound Imaging in Parathyroid Disease
Previous Article in Journal
RDW as A Predictor for No-Reflow Phenomenon in DM Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Previous Article in Special Issue
Introducing a Pole Concept for Nodule Growth in the Thyroid Gland: Taller-than-Wide Shape, Frequency, Location and Risk of Malignancy of Thyroid Nodules in an Area with Iodine Deficiency
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 12
Issue 3
10.3390/jcm12030812
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Evolving Role of [18F]Flurocholine PET/CT in Assessing Primary Hyperparathyroidism: Can It Be Considered the First-Line Functional Imaging Approach?

by
Seyedeh Sara Seyedinia
1,†,
Seyed Ali Mirshahvalad
1,2,†,
Gregor Schweighofer-Zwink
1,
Lukas Hehenwarter
1,
Gundula Rendl
1,
Christian Pirich
1 and
Mohsen Beheshti
1,*
1
Division of Molecular Imaging & Theranostics, Department of Nuclear Medicine, University Hospital Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria
2
Joint Department of Medical Imaging, University Health Network, University of Toronto, Toronto, ON M5G 2M2, Canada
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
J. Clin. Med. 2023, 12(3), 812; https://doi.org/10.3390/jcm12030812
Submission received: 28 November 2022 / Revised: 25 December 2022 / Accepted: 17 January 2023 / Published: 19 January 2023
(This article belongs to the Special Issue Imaging in Endocrine Diseases and Neuroendocrine Tumors)
Browse Figures
Review Reports Versions Notes

Abstract

:
The accurate detection of hyperfunctioning parathyroid tissue (HFPT) is pivotal in the preoperative assessment of primary hyperparathyroidism (PHPT). PET/CT using [18F]fluorocholine ([18F]FCH) showed superior diagnostic performance compared to conventional functional imaging modalities. We aimed to evaluate the diagnostic performance of [18F]FCH PET/CT as a first-line functional imaging approach in patients with clinically diagnosed PHPT. The imaging and clinical data of 321 PHPT patients, including 271 overt PHPT and 50 mild PHPT, who underwent [18F]FCH PET/CT as first-line imaging were analysed in this retrospective study. Histopathology was the reference standard. In case of no available histopathology evaluation (conservative management), imaging and clinical follow-ups were considered reference standards. In the overt group (n = 271), [18F]FCH PET/CT showed sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of 0.99, 0.91, 1.00, 0.80, and 0.99, respectively. Regarding the correlation of the index lesions and initial laboratory data, all [18F]FCH PET/CT parameters (SUVs, SULs, and mSAD) were significantly correlated with the serum iPTH level. Additionally, SUVmax, SULpeak, and mSAD were significantly associated with the serum calcium level. In the mild group (n = 50), [18F]FCH PET/CT showed a sensitivity, specificity, PPV, NPV, and accuracy of 0.93, 0.75, 0.95, 0.67, and 0.90. In conclusion, [18F]FCH PET/CT revealed high diagnostic performance in the detection of HFPTs and the potential to be considered as a first-line imaging modality in the assessment of PHPT, including both overt and mild types. However, its cost–benefit concerning the clinical impact of early PHPT detection should be investigated in future studies.

1. Introduction

Primary hyperparathyroidism (PHPT) is the third most common endocrine disorder. It is characterized by elevated or inappropriately normal parathyroid hormone serum (PTH) levels due to single or multiple hyperactive parathyroid glands [1]. Parathyroid adenoma is the most common type of PHPT, followed by multi-glandular disease (MGD), parathyroid hyperplasia, and rarely parathyroid carcinoma [1].
The overt PHTP (oPHPT) is defined as an elevated serum level of calcium following an increase in PTH, leading to further clinical symptoms [2,3,4]. This is the classic definition of PHPT, which has been considered clinically significant for decades. However, routine determination of the serum calcium as a biochemical-screening tool resulted in the identification of asymptomatic patients with borderline biochemical results [5]. Thus, the term mild PHPT (mPHPT) was introduced. mPHPT is considered a different entity regarding histopathology and management, and has been categorized into two different groups, Normohormonal mPHPT (NHmPHPT) and Normocalcemic mPHPT (NCmPHPT) [6,7]. Approximately half of mPHPT patients and two-thirds of NHmPHPT cases experience at least one non-specific symptom, only to be recognized upon questioning [5,8].
Surgical removal of parathyroid adenoma(s) is the curative approach for PHPT [9]. Minimally invasive parathyroidectomy (MIP) is currently the procedure of choice with fewer morbid events compared to the traditional bilateral neck exploration (BNE) [10,11]. Precise preoperative localization of the hyperfunctioning parathyroid tissue(s) (HFPT) is necessary to perform MIP and may prevent persistent/recurrent PHPT and re-operation. Noteworthy, considering only mPHPT patients, decision-making is more challenging since surgery is still controversial, especially in asymptomatic patients [5]. Additionally, hesitation still exists among surgeons because of the higher surgical failure compared to oPHPT (5% vs. 1%), due to the higher incidence of multiglandular disease (as high as 35%) and smaller size of the adenoma(s) [5,7,12,13,14,15].
Cervical ultrasonography (cUS) and parathyroid scintigraphy with [99mTc]Tc-Methoxy-IsoButyl-Isonitrol ([99mTc]Tc-MIBI) is the first-line imaging modalities for preoperative detection and localization of HFPT [16]. However, cUS is an operator-dependent modality with limited diagnostic performance in the presence of small adenomas and ectopic glands [17]. Considering [99mTc]Tc-MIBI, in a meta-analysis by Wei et al., single photon emission computed tomography/computed tomography (SPECT/CT) and SPECT had sensitivities of 0.84 and 0.66, respectively [18]. [99mTc]Tc-MIBI has also revealed limited performance, particularly in the presence of small parathyroid adenoma or MGD [19]. Furthermore, anatomical imaging, including CT and magnetic resonance imaging (MRI), revealed limited impact in assessing PHPT. The reported sensitivities of CT for the detection of HFPTs range 0.46–0.87. Additionally, the diagnostic performance of MRI for accurate identification of HFPTs is highly dependent on their typical morphology and location [20].
18F-flurocholine ([18F]FCH) is an analogue of phospholipid that binds to a new synthetised membrane. HFPT functioning parathyroid tissues upregulate the expression of 2+Calcium-dependent choline kinase receptors, resulting in increased [18F]FCH uptake [21]. Furthermore, [18F]FCH PET/CT provides higher spatial resolution enabling the detection of smaller lesions [11,22]. In our previous prospective dual-centre study, we found the superiority of [18F]FCH PET/CT in the detection and localization of parathyroid adenomas compared to [99mTc]Tc-MIBI SPECT/CT as a standard of care imaging [11]. Meanwhile, several other studies have demonstrated similar results. Thanks to the available PET/CT scanners and radiopharmaceutical facilities nowadays, the question is raised if [18F]FCH PET/CT can be performed as the first-line preoperative imaging modality. Thus, in the current study, we aimed to evaluate the diagnostic performance of [18F]FCH PET/CT as the first-line preoperative imaging in a large patient population with clinically diagnosed PHPT.

2. Materials and Methods

2.1. Study Population

This IRB-approved study was performed in accordance with the ethical standards of the institutional ethics committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Overall, 360 consecutive patients with the initial diagnosis of PHPT who underwent [18F]FCH PET/CT from January 2015 to December 2021 were included in this study. Exclusion criteria were the initial diagnosis of secondary/tertiary hyperparathyroidism (n = 11), as well as vitamin D deficiency (n = 4), and familial hypocalciuric hypercalcemia (n = 4) that were diagnosed after further investigation. Moreover, patients without reliable follow-up clinical or imaging data (n = 19) and poor quality of the [18F]FCH PET/CT imaging (n = 1) were also excluded. To precisely evaluate our cohort and prevent possible biases, we divided the patients into two groups: oPHPT (n = 271) and mPHPT (n = 50). The definitions and overall characteristics are provided in the supplemental materials. oPHPT was defined as elevated serum levels of both iPTH and calcium. Patients with the diagnosis of mPHPT were: (a) NCmPHPT: patients with normal serum calcium levels and elevated serum intact iPTH levels; and (b) NHmPHPT: patients with normal serum iPTH levels and elevated serum calcium levels.

2.2. [18F]FCH PET/CT Acquisition and Interpretation

Detailed acquisition and image interpretation protocols are provided in the supplemental materials. The number and location of the abnormal lesions were noted. The location of parathyroid lesions was categorized into two groups, upper parathyroid glands (P4) and lower parathyroid glands (P3) [23]. These regions were correlated with the surgical resection reports to find the corresponding gland. The semi-quantitative parameters, including maximum standard uptake value (SUVmax), average SUV (SUVmean), peak and average SUV normalized by lean body mass (SULpeak and SULmean, respectively), were measured within a selected iso-contour sphere as the volume of interest (VOI), with a predefined threshold of 41%. The maximum metabolic short-axis diameters (mSAD) of the abnormal parathyroid lesion were determined on the PET images.

2.3. Reference Standard

The final diagnosis was based on histopathological results in patients who underwent surgery (all underwent the MIP procedure, except for three). The interval between PET/CT imaging and surgery was no longer than one month (mean days interval = 21 ± 8). A successful resection was considered as >50% intraoperative iPTH decline compared to the baseline iPTH and decreasing pattern of iPTH and calcium in the laboratory follow-ups within six months after surgery. Pathologic parathyroid specimens were reported as adenoma, hyperplasia, or carcinoma. In patients with negative parathyroid pathology, the presence of thymus tissue, thyroid nodules, or lymph nodes was extracted. Histopathological results were considered the reference standard for the resected glands. Additional information was gathered from the pathology reports, including the size and weight of the parathyroid lesions.
In the group of oPHPT patients who underwent the conservative approach, imaging (e.g., follow-up US or [99mTc]Tc-MIBI imaging) and/or clinical (laboratory evaluation) follow-ups were considered the reference standard. A 6-month follow-up included laboratory data (serum level of iPTH and calcium) and cUS. In patients with MGD, the lesion with the highest [18F]FCH uptake was defined as index-lesion for the analyses.
Clinical and imaging follow-ups were considered the reference standard in the group of mPHPT patients who underwent the conservative approach. In the NCmPHPT and NHmPHPT patients, normalized iPTH and calcium or a more than 50% decrease in iPTH from the baseline value was considered significant.
The detailed definitions of true-positive (TP), true-negative (TN), false-positive (FP), and false-negative (FN) results can be found in the supplemental materials (Tables S1 and S2).

2.4. Statistical Analysis

Continuous variables were expressed as mean values with standard deviations (SD). Non-parametric t-test was applied to determine the significance of differences for continuous variables. Categorical variables were expressed as number and frequency. Diagnostic performances were calculated, including sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy. According to the reference standard, the receiver operating characteristic (ROC) curves fitted for sensitivity and specificity were drawn. Additionally, the area under the curve (AUC) was calculated. All statistical analyses were performed using SPSS (ver.26, IBM) software. A two-tailed p-value of <0.05 was considered statistically significant.

3. Results

3.1. oPHPT Population

Patient-Based Analysis

In 271 patients, [18F]FCH PET/CT showed TP, TN, FP, and FN results in 257, 10, 1, and 3 patients, respectively. Table 1 provides details about the included patients. Table 2 shows detailed initial and follow-up laboratory results of the included patients.
In the patient-based analyses, [18F]FCH PET/CT showed sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of 0.99, 0.91, 1.00, 0.80, and 0.99, respectively.
Overall, 24 (24/271, 9%) patients revealed abnormal [18F]FCH uptake in more than one location (13 patients with two, 9 patients with three, and 2 patients with four lesions) suggestive of MGD (Figure 1). In this group, 14 patients underwent the surgical approach, and 10 followed up with conservative management. No significant differences were found between laboratory parameters of patients with MGD compared to single glandular disease (p-values > 0.05).
There were three patients with evidence of persistent iPTH or Calcium on follow-up. All these patients had positive [18F]FCH PET/CT and pathology results. After a retrospective review of the [18F]FCH PET/CT images in one of them, we noticed evidence of additional mild small radiotracer uptake suggestive of parathyroid adenoma that could be the reason for persistent laboratory results. Two other patients had positive [18F]FCH PET/CT results, but the available pathology reports were negative for HFPT. These patients showed a more than 50% decrease in iPTH during the surgery, and iPTH remained in the normal range years after the surgery.
Three patients in the FN group had negative [18F]FCH PET/CT results and increased levels of iPTH (n = 2) or Calcium (n = 1) on the follow-up. Only one patient was considered as FP. In this case, [18F]FCH PET/CT localized one lesion suggesting HFPT, and subsequent surgery was performed. However, the pathology report was negative for HFPT. The iPTH serum levels showed initially <50% decline after surgery but an increasing pattern in the clinical follow-ups. No information was available about intraoperative iPTH assessment in this case, as the surgery was performed in another hospital.

3.2. Lesion-Based Analysis

Metabolic characteristics (mean ± SD) SUVmax, SUVmean, SULpeak, SULmean, and mSAD of index lesions (n = 257) were 9.1 ± 3.6, 5.3 ± 1.8, 6.3 ± 2.5 and 3.7 ± 1.3, and 8 ± 5 mm, respectively. Moreover, histology characteristics, including size and weight of the positive lesions, were 17 ± 7 mm and 1.2 ± 1.7 g, respectively. From a total of 309 pathologic lesions, 231 were considered P4, and 78 were P3. Eighteen patients (7%) had ectopic glands, including fourteen P4 lesions and four P3 lesions. Thirteen ectopic P4 lesions were identified in the mediastinum and one in the paravertebral region. Three P3 ectopic glands were ectopic cervical adenomas, and one was an intrathyroidal adenoma. Figure 2 shows a patient with pathology-proven ectopic parathyroid adenoma.
Regarding the correlation of the index lesions and initial laboratory data, all [18F]FCH PET/CT parameters (SUVs, SULs, and mSAD) were significantly correlated with the serum iPTH level. Additionally, SUVmax, SULpeak, and mSAD were significantly associated with the serum calcium level. Details are provided in Table 3. Other laboratory parameters, including phosphorus, alkaline phosphatase, and creatinine, showed no significant correlation with the semi-quantitative findings on [18F]FCH PET/CT (p-values > 0.05). Furthermore, there was a significant correlation between SUV values on [18F]FCH PET and histopathology reports, including size and weight (p-values < 0.05). SUVmean was the only semi-quantitative parameter of [18F]FCH PET/CT, which was significantly different between parathyroid adenomas and hyperplasia (p-value < 0.05, Figure 3). However, based on clinical and imaging findings, accurate differentiation between various HFPTs was not possible.

4. mPHPT Population

A total number of 50 patients (mean age= 67 ± 12 years) was studied, including 39 (78%) patients with NCmPHPT and 11 (22%) patients with NHmPHPT disease. Detailed characteristics are provided in Table 1. In the NCmPHPT group, 32/39 (82%) patients showed positive results on [18F]FCH PET/CT images. In the NHmPHPT group, 9/11 (82%) patients were positive. There were no significant differences in semi-quantitative parameters between NCmPHPT and NHmPHPT patients (p-values > 0.05). Out of 39 NCmPHPT patients, 19 (49%) underwent surgical resection of the positive [18F]FCH PET/CT gland. Detailed histopathology findings can be found in Table 4. In the NHmPHPT group, 4/11 (36%) patients were planned for surgery. MIP was performed for all patients except three who underwent BNE; two were NCmPHPT, and one was in the NHmPHPT group. Pathology found at least one parathyroid adenoma in all patients with positive scans, except for an NCmPHPT patient with only one hyperplastic gland on pathology. In this patient, iPTH decreased more than 50% at the 6-month follow-up. In the remaining patients, including 20 NCmPHPT and 7 NHmPHPT patients, follow-up laboratory results were considered the reference standard. In the NCmPHPT patients, 11, 4, 2, and 3 were categorized in TP, TN, FP, and FN results, respectively. In the NHmPHPT patients, follow-up revealed 5 TP and 2 TN cases. Overall, [18F]FCH PET/CT showed a sensitivity, specificity, PPV, NPV, and accuracy of 0.93, 0.75, 0.95, 0.67, and 0.90.
Since this group of patients was more controversial in terms of management, except for one NCmPHPT case, all patients underwent cUS examination. A comparison of findings between [18F]FCH PET/CT, cUS, and the final diagnosis is provided in Table 5. We analysed the [18F]FCH PET/CT versus cUS performances in these 49 patients. In NCmPHPT patients, sensitivity, specificity, and accuracy of [18F]FCH PET/CT vs. cUS were 0.91 vs. 0.38, 0.67 vs. 0.83, and 0.84 vs. 0.45, respectively. In NHmPHP group, sensitivity, specificity, and accuracy of [18F]FCH PET/CT vs. cUS were 1.00 vs. 0.44, 1.00 vs. 0.50, and 1.00 vs. 0.45, respectively. ROC curves were drawn for [18F] FCH PET/CT vs. cUS, showing AUCs of 0.84 vs. 0.57 (Figure 4).

5. Discussion

[18F]FCH PET/CT holds promising diagnostic performance for becoming the first-line imaging modality for accurate detection and localization of HFPT in PHPT patients. To our knowledge, this study assessed the impact of [18F]FCH PET/CT as first-line imaging in the largest patient population to date, including both oPHPT and mPHPT. The results of the current study can support the high diagnostic performance of [18F]FCH PET/CT in oPHPT with a sensitivity, specificity, PPV, NPV, and accuracy of 0.99, 0.91, 1.00, 0.80, and 0.99, respectively. Additionally, it showed high accuracy in mPHPT patients. Interestingly, [18F]FCH PET/CT could detect and localize HFPTs in all NHmPHPT patients accurately.
Localization of HFPT is mandatory before resection to reduce the risk of further surgical failure [24]. Based on the findings of our initial prospective research in PHPT patients comparing [18F]FCH PET/CT with [99mTc]Tc-MIBI SPECT/CT, [18F]FCH PET/CT showed superiority to be the first-line functional imaging modality in our centre [11]. We reported detection rates of 0.93 and 0.61 for [18F]FCH PET/CT and [99mTc]Tc-MIBI SPECT/CT, respectively. However, in most centres worldwide, [99mTc]Tc-MIBI SPECT/CT is still considered the modality of choice following current clinical guidelines for the localization of HFPT before the surgery [11,25,26,27,28,29,30]. Regarding its limitations, [99mTc]Tc-MIBI scintigraphy provided low sensitivity and high numbers of FN results [11,24,31]. Moreover, its sensitivity was even lower in specific conditions, including MGD and ectopic adenoma [11,16,24,31]. Danovan et al. reported an overall sensitivity of 0.58 [32]. While in the presence of solitary adenoma, the sensitivity was 0.78, it dropped to 0.31 in MGD patients [32]. Another important shortcoming of [99mTc]Tc-MIBI was the detection of small adenomas, showing a limited accuracy in small HFPTs with a median weight of 0.5 g [31]. In addition, the diagnostic performance of [99mTc]Tc-MIBI was very limited in NCmPHPT patients in the study by Gomez- Ramirez et al. [33]. They proposed the hypothesis that the lower level of iPTH decreases the [99mTc]Tc-MIBI diagnostic capability. Thus, considering mPHPT as a similar entity to oPHPT, may not be a ground truth from the imaging perspective. Furthermore, although the combination of planar and SPECT/CT parathyroid scintigraphy increased the sensitivity up to 0.86 in PHPT patients, again, [99mTc]Tc-MIBI suffered from acceptable diagnostic performance in mPHPT patients [13,34]. Musumeci et al. reported a sensitivity of 0.59 for [99mTc]Tc-MIBI SPECT/CT in mPHPT compared to 0.86 in oPHPT, which was similar to Gomez-Ramirez et al. [10,33]. Additionally, [18F]FCH PET/CT provides higher spatial resolution and lesion to background ratio [9], semi-quantitative assessment, shorter imaging time [11,31], and lower radiation dose (2.8 mSv vs. 6.8 mSv) compared to [99mTc]Tc-MIBI SPECT/CT [22,35,36]. Moreover, there is no need to discontinue calcimimetic drugs before [18F]FCH PET/CT [22].
Our previous study revealed that [99mTc]Tc-MIBI SPECT/CT imaging was falsely negative in adenomas <13 mm [11]. Similar findings were reported in other studies, showing that [99mTc]Tc-MIBI SPECT/CT were mostly negative in HFPT ≤12mm [37,38]. In the current study, 61% (130/241) of surgically removed HFPT were reported to be ≤15 mm on the histopathology. [18F]FCH PET/CT correctly detected all of these small lesions, which can support the potential of this modality in detecting small HFPTs.
Several previously published studies have evaluated [18F]FCH PET/CT as the first-line imaging modality in PHPT. Cuderman et al. showed that [18F]FCH PET/CT is a diagnostic modality superior to conventional imaging [31]. Wouter et al. assessed [18F]FCH PET/CT as an exclusive imaging modality and reported a detection rate of 96% on per-patient and 90% on per-lesion analysis in 139 PHPT patients who underwent surgery [22]. Although the initial population in this study was larger, the final analysis was performed only in a subgroup that underwent surgery. Bossert et al. recently reported [18F]FCH PET/CT as an effective imaging modality in NCmPHPT [39]. Notably, they also indicated [18F]FCH PET/CT as a cost-effective modality due to its high diagnostic performance and accurate pre-surgical localization of HFPTs. However, they compared oPHPT (n = 27) with limited NCmPHPT patients (n = 7) and did not evaluate NHmPHPT. In contrast, in the current study, we tried to assess the diagnostic performance of [18F]FCH PET/CT in a larger population and evaluated NHmPHPT patients as well.
The impact of [18F]FCH PET/CT in detecting MGD and ectopic parathyroid adenomas has been discussed in the literature. Most studies reported promising results emphasizing the potential of [18F]FCH PET/CT to overcome the limitations of other modalities, as well as the determination of the lipomatous parathyroid adenomas [16,26,40,41]. In contrast, some limited studies revealed a probability of FP findings on [18F]FCH PET/CT imaging [31,42]. Our result may support that [18F]FCH PET/CT is an accurate modality in MGD patients. This was of great clinical importance considering the limited sensitivity of the intraoperative iPTH approach in MGD, which may lead to premature surgical termination, prolongation of the surgery time, and an increase in the total costs [31,43]. Of note, the retrospective nature of our study might influence our results.
Few previous studies assessed the correlation between metabolic parameters derived by [18F]FCH PET/CT and serum levels of iPTH and calcium. Alharbi et al. found a strong correlation between SUVmax of the positive lesion and serum level of iPTH [44]. Other studies reported a strong correlation between serum levels of calcium and SUVmax [30,45]. We also found strong correlations between all semi-quantitative metabolic parameters and serum iPTH levels. In terms of the serum calcium level, SUVmax and SULpeak showed a significant correlation in the current study.
One of the limitations of our study was the lack of histopathologic confirmation in patients who underwent the conservative approach. Although the laboratory results could characterize patients to some extent, histopathology is the gold standard for a definite diagnosis. Additionally, the retrospective design of the study could affect the calculated performances. Moreover, only a limited number of genetic test results were available in medical records, and urinary calcium measurement was performed only in a few patients with clinically suspicious familial hypocalciuric hypercalcemia. Therefore, providing a reliable analysis was not possible. Lastly, the number of mPHPT patients, especially in the NHmPHPT group, was limited.

6. Conclusions

In conclusion, this study revealed a high diagnostic performance of [18F]FCH PET/CT in detecting HFPTs in both oPHPT and mPHPT patients. Thus, adding our results to the current literature, [18F]FCH PET/CT can be considered as first-line imaging for assessing PHPT in terms of diagnostic accuracy. Additionally, preliminary studies showed [18F]FCH PET/CT to be a potentially cost-effective modality in this regard [39,46], though further cost–utility investigations are mandatory to recommend [18F]FCH PET/CT as a routine modality in the clinic.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm12030812/s1, Table S1: Definition of the [18F] FCH PET/CT findings compared to the reference standard in oPHPT group; Table S2: Definition of the [18F] FCH PET/CT findings compared to the reference standard in mPHPT group.

Author Contributions

Conceptualization, M.B. and C.P.; methodology, M.B and S.S.S.; formal Analysis, S.A.M.; investigation, S.S.S. and S.A.M.; data curation, S.S.S.; writing—original draft preparation, S.S.S. and S.A.M.; writing—Review and Editing, G.S.-Z., L.H., G.R., C.P., M.B. and S.A.M.; visualization, S.S.S. and S.A.M.; supervision, M.B. and C.P.; project administration, M.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board and Ethics Committee of University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria. Identification code: 415-E/1858/7-2015. EudraCT: 2015-00411-40. Date of approval: 4 April 2015.

Informed Consent Statement

Informed consent was obtained from all subjects presented in the study.

Data Availability Statement

The data presented in this study are available on request from the corresponding author.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Amaral, L.M.; Queiroz, D.C.; Marques, T.F.; Mendes, M.; Bandeira, F. Normocalcemic versus Hypercalcemic Primary Hyperparathyroidism: More Stone than Bone? J. Osteoporos. 2012, 2012, 128352. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Silverberg, S.J.; Clarke, B.L.; Peacock, M.; Bandeira, F.; Boutroy, S.; Cusano, N.E.; Dempster, D.; Lewiecki, E.M.; Liu, J.M.; Minisola, S.; et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: Proceedings of the Fourth International Workshop. J. Clin. Endocrinol. Metab. 2014, 99, 3580–3594. [Google Scholar] [CrossRef] [PubMed]
  3. Lecourt, A.; Creff, G.; Coudert, P.; de Crouy Chanel, O.; Guggenbuhl, P.; Jegoux, F. Surgical management of MILD hyperparathyroidism. Eur. Arch. Otorhinolaryngol. 2021, 278, 3901–3910. [Google Scholar] [CrossRef]
  4. Dandurand, K.; Ali, D.S.; Khan, A.A. Primary Hyperparathyroidism: A Narrative Review of Diagnosis and Medical Management. J. Clin. Med. 2021, 10, 1604. [Google Scholar] [CrossRef] [PubMed]
  5. Applewhite, M.K.; Schneider, D.F. Mild primary hyperparathyroidism: A literature review. Oncologist 2014, 19, 919–929. [Google Scholar] [CrossRef] [Green Version]
  6. Tordjman, K.M.; Greenman, Y.; Osher, E.; Shenkerman, G.; Stern, N. Characterization of normocalcemic primary hyperparathyroidism. Am. J. Med. 2004, 117, 861–863. [Google Scholar] [CrossRef] [PubMed]
  7. Gómez-Ramírez, J.; Mihai, R. Normocalcaemic primary hyperparathyroidism: A diagnostic and therapeutic algorithm. Langenbecks Arch. Surg. 2017, 402, 1103–1108. [Google Scholar] [CrossRef] [PubMed]
  8. Adler, J.T.; Sippel, R.S.; Schaefer, S.; Chen, H. Surgery improves quality of life in patients with “mild” hyperparathyroidism. Am. J. Surg. 2009, 197, 284–290. [Google Scholar] [CrossRef]
  9. Ferrari, C.; Santo, G.; Mammucci, P.; Pisani, A.R.; Sardaro, A.; Rubini, G. Diagnostic Value of Choline PET in the Preoperative Localization of Hyperfunctioning Parathyroid Gland(s): A Comprehensive Overview. Biomedicines 2021, 9, 231. [Google Scholar] [CrossRef]
  10. Musumeci, M.; Pereira, L.V.; San Miguel, L.; Cianciarelli, C.; Vazquez, E.C.; Mollerach, A.M.; Arma, I.J.; Hume, I.; Galich, A.M. Normocalcemic primary hyperparathyroidism: 99mTc SestaMibi SPECT/CT results compare with hypercalcemic hyperparathyroidism. Clin. Endocrinol. 2022, 96, 831–836. [Google Scholar] [CrossRef]
  11. Beheshti, M.; Hehenwarter, L.; Paymani, Z.; Rendl, G.; Imamovic, L.; Rettenbacher, R.; Tsybrovskyy, O.; Langsteger, W.; Pirich, C. (18)F-Fluorocholine PET/CT in the assessment of primary hyperparathyroidism compared with (99m)Tc-MIBI or (99m)Tc-tetrofosmin SPECT/CT: A prospective dual-centre study in 100 patients. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 1762–1771. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Mainali, B.; Lindeman, B.; Chen, H. Re-operative Parathyroidectomy in Patients With Mild Primary Hyperparathyroidism. J. Surg. Res. 2020, 255, 130–134. [Google Scholar] [CrossRef] [PubMed]
  13. Trébouet, E.; Bannani, S.; Wargny, M.; Leux, C.; Caillard, C.; Kraeber-Bodéré, F.; Renaudin, K.; Chaillous, L.; Mirallié, É.; Ansquer, C. Mild sporadic primary hyperparathyroidism: High rate of multiglandular disease is associated with lower surgical cure rate. Langenbecks Arch. Surg. 2019, 404, 431–438. [Google Scholar] [CrossRef] [PubMed]
  14. Schneider, D.F.; Burke, J.F.; Ojomo, K.A.; Clark, N.; Mazeh, H.; Sippel, R.S.; Chen, H. Multigland disease and slower decline in intraoperative PTH characterize mild primary hyperparathyroidism. Ann. Surg. Oncol. 2013, 20, 4205–4211. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Dutta, D.; Gupta, P.K.; Sharma, M.; Damble, N.A.; Madan, R.; Dogra, S. (18)F-Fluorocholine-Positron Emission Tomography/Computerised Tomography is Useful in Localising (99m)Tc-Sesta-methoxyisobutylisonitrile-Negative Parathyroid Cyst Causing Normocalcemic Primary Hyperparathyroidism. Eur. Endocrinol. 2018, 14, 56–58. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Boccalatte, L.A.; Higuera, F.; Gómez, N.L.; de la Torre, A.Y.; Mazzaro, E.L.; Galich, A.M.; Collaud, C.; Figari, M.F. Usefulness of 18F-Fluorocholine Positron Emission Tomography-Computed Tomography in Locating Lesions in Hyperparathyroidism: A Systematic Review. JAMA Otolaryngol. Head Neck Surg. 2019, 145, 743–750. [Google Scholar] [CrossRef]
  17. Andrioli, M.; Valcavi, R. Sonography of Normal and Abnormal Thyroid and Parathyroid Glands. Front. Horm. Res. 2016, 45, 1–15. [Google Scholar]
  18. Wei, W.J.; Shen, C.T.; Song, H.J.; Qiu, Z.L.; Luo, Q.Y. Comparison of SPET/CT, SPET and planar imaging using 99mTc-MIBI as independent techniques to support minimally invasive parathyroidectomy in primary hyperparathyroidism: A meta-analysis. Hell J. Nucl. Med. 2015, 18, 127–135. [Google Scholar]
  19. Kannan, S.; Milas, M.; Neumann, D.; Parikh, R.T.; Siperstein, A.; Licata, A. Parathyroid nuclear scan. A focused review on the technical and biological factors affecting its outcome. Clin. Cases Min. Bone Metab. 2014, 11, 25–30. [Google Scholar] [CrossRef]
  20. Johnson, N.A.; Tublin, M.E.; Ogilvie, J.B. Parathyroid Imaging: Technique and Role in the Preoperative Evaluation of Primary Hyperparathyroidism. Am. J. Roentgenol. 2007, 188, 1706–1715. [Google Scholar] [CrossRef]
  21. van der Hiel, B.; Stokkel, M.P.; Buikhuisen, W.A.; Janssen, H.; van Velthuysen, M.L.; Rhodius, R.J.; Vogel, W.V. 18F-Choline PET/CT as a New Tool for Functional Imaging of Non-Proliferating Secreting Neuroendocrine Tumors. J. Endocrinol. Metab. 2015, 5, 4. [Google Scholar] [CrossRef] [Green Version]
  22. Broos, W.A.; Wondergem, M.; Knol, R.J.; van der Zant, F.M. Parathyroid imaging with (18)F-fluorocholine PET/CT as a first-line imaging modality in primary hyperparathyroidism: A retrospective cohort study. EJNMMI Res. 2019, 9, 72. [Google Scholar] [CrossRef] [PubMed]
  23. Hindié, E.; Ugur, Ö.; Fuster, D.; ODoherty, M.; Grassetto, G.; Ureña, P.; Kettle, A.; Gulec, S.A.; Pons, F.; Rubello, D. 2009 EANM parathyroid guidelines. Eur. J. Nucl. Med. Mol. Imaging 2009, 36, 1201–1216. [Google Scholar] [CrossRef] [PubMed]
  24. Dudoignon, D.; Delbot, T.; Cottereau, A.S.; Dechmi, A.; Bienvenu, M.; Koumakis, E.; Cormier, C.; Gaujoux, S.; Groussin, L.; Cochand-Priollet, B.; et al. 18F-fluorocholine PET/CT and conventional imaging in primary hyperparathyroidism. Diagn Interv. Imaging 2022, 103, 258–265. [Google Scholar] [CrossRef]
  25. Michaud, L.; Balogova, S.; Burgess, A.; Ohnona, J.; Huchet, V.; Kerrou, K.; Lefèvre, M.; Tassart, M.; Montravers, F.; Périé, S.; et al. A Pilot Comparison of 18F-fluorocholine PET/CT, Ultrasonography and 123I/99mTc-sestaMIBI Dual-Phase Dual-Isotope Scintigraphy in the Preoperative Localization of Hyperfunctioning Parathyroid Glands in Primary or Secondary Hyperparathyroidism: Influence of Thyroid Anomalies. Medicine 2015, 94, e1701. [Google Scholar]
  26. Kluijfhout, W.P.; Vorselaars, W.M.; van den Berk, S.A.; Vriens, M.R.; Borel Rinkes, I.H.; Valk, G.D.; van Dalen, T.; de Klerk, J.M.; de Keizer, B. Fluorine-18 fluorocholine PET-CT localizes hyperparathyroidism in patients with inconclusive conventional imaging: A multicenter study from the Netherlands. Nucl. Med. Commun. 2016, 37, 1246–1252. [Google Scholar] [CrossRef] [PubMed]
  27. Quak, E.; Blanchard, D.; Houdu, B.; Le Roux, Y.; Ciappuccini, R.; Lireux, B.; de Raucourt, D.; Grellard, J.M.; Licaj, I.; Bardet, S.; et al. F18-choline PET/CT guided surgery in primary hyperparathyroidism when ultrasound and MIBI SPECT/CT are negative or inconclusive: The APACH1 study. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 658–666. [Google Scholar] [CrossRef] [Green Version]
  28. Huber, G.F.; Hüllner, M.; Schmid, C.; Brunner, A.; Sah, B.; Vetter, D.; Kaufmann, P.A.; Von Schulthess, G.K. Benefit of (18)F-fluorocholine PET imaging in parathyroid surgery. Eur. Radiol. 2018, 28, 2700–2707. [Google Scholar] [CrossRef]
  29. Araz, M.; Soydal, Ç.; Özkan, E.; Kir, M.K.; İbiş, E.; Güllü, S.; Erdoğan, M.F.; Emral, R.; Küçük, Ö.N. The efficacy of fluorine-18-choline PET/CT in comparison with 99mTc-MIBI SPECT/CT in the localization of a hyperfunctioning parathyroid gland in primary hyperparathyroidism. Nucl. Med. Commun. 2018, 39, 989–994. [Google Scholar] [CrossRef]
  30. Piccardo, A.; Trimboli, P.; Rutigliani, M.; Puntoni, M.; Foppiani, L.; Bacigalupo, L.; Crescenzi, A.; Bottoni, G.; Treglia, G.; Paparo, F.; et al. Additional value of integrated (18)F-choline PET/4D contrast-enhanced CT in the localization of hyperfunctioning parathyroid glands and correlation with molecular profile. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 766–775. [Google Scholar] [CrossRef]
  31. Cuderman, A.; Senica, K.; Rep, S.; Hocevar, M.; Kocjan, T.; Sever, M.J.; Zaletel, K.; Lezaic, L. (18)F-Fluorocholine PET/CT in Primary Hyperparathyroidism: Superior Diagnostic Performance to Conventional Scintigraphic Imaging for Localization of Hyperfunctioning Parathyroid Glands. J. Nucl. Med. 2020, 61, 577–583. [Google Scholar] [CrossRef] [PubMed]
  32. Tay, D.; Das, J.P.; Yeh, R. Preoperative Localization for Primary Hyperparathyroidism: A Clinical Review. Biomedicines 2021, 9, 390. [Google Scholar] [CrossRef] [PubMed]
  33. Gómez-Ramírez, J.; Gómez-Valdazo, A.; Luengo, P.; Porrero, B.; Osorio, I.; Rivas, S. Comparative prospective study on the presentation of normocalcemic primary hyperparathyroidism. Is it more aggressive than the hypercalcemic form? Am. J. Surg. 2020, 219, 150–153. [Google Scholar] [CrossRef]
  34. Wong, K.K.; Fig, L.M.; Gross, M.D.; Dwamena, B.A. Parathyroid adenoma localization with 99mTc-sestamibi SPECT/CT: A meta-analysis. Nucl. Med. Commun. 2015, 36, 363–375. [Google Scholar] [CrossRef] [PubMed]
  35. Rep, S.; Hocevar, M.; Vaupotic, J.; Zdesar, U.; Zaletel, K.; Lezaic, L. (18)F-choline PET/CT for parathyroid scintigraphy: Significantly lower radiation exposure of patients in comparison to conventional nuclear medicine imaging approaches. J. Radiol. Prot. 2018, 38, 343–356. [Google Scholar] [CrossRef]
  36. Treglia, G.; Piccardo, A.; Imperiale, A.; Strobel, K.; Kaufmann, P.A.; Prior, J.O.; Giovanella, L. Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: A systematic review and meta-analysis. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 751–765. [Google Scholar] [CrossRef]
  37. Hayakawa, N.; Nakamoto, Y.; Kurihara, K.; Yasoda, A.; Kanamoto, N.; Miura, M.; Inagaki, N.; Togashi, K. A comparison between 11C-methionine PET/CT and MIBI SPECT/CT for localization of parathyroid adenomas/hyperplasia. Nucl. Med. Commun. 2015, 36, 53–59. [Google Scholar] [CrossRef] [Green Version]
  38. Carral, F.; Jiménez, A.I.; Tomé, M.; Álvarez, J.; Díez, A.; Partida, F.; Ayala, C. Factors associated with negative (99m)Tc-MIBI scanning in patients with primary hyperparathyroidism. Rev. Esp. Med. Nucl. Imagen. Mol. 2021, 40, 222–228. [Google Scholar]
  39. Bossert, I.; Chytiris, S.; Hodolic, M.; Croce, L.; Mansi, L.; Chiovato, L.; Mariani, G.; Trifirò, G. PETC/CT with (18)F-Choline localizes hyperfunctioning parathyroid adenomas equally well in normocalcemic hyperparathyroidism as in overt hyperparathyroidism. J. Endocrinol. Investig. 2019, 42, 419–426. [Google Scholar] [CrossRef]
  40. Giovanella, L.; Bacigalupo, L.; Treglia, G.; Piccardo, A. Will (18)F-fluorocholine PET/CT replace other methods of preoperative parathyroid imaging? Endocrine 2021, 71, 285–297. [Google Scholar] [CrossRef]
  41. Orevi, M.; Freedman, N.; Mishani, E.; Bocher, M.; Jacobson, O.; Krausz, Y. Localization of parathyroid adenoma by ¹¹C-choline PET/CT: Preliminary results. Clin. Nucl. Med. 2014, 39, 1033–1038. [Google Scholar] [CrossRef] [PubMed]
  42. Thanseer, N.T.; Bhadada, S.K.; Sood, A.; Mittal, B.R.; Behera, A.; Gorla, A.K.; Kalathoorakathu, R.R.; Singh, P.; Dahiya, D.; Saikia, U.N.; et al. Comparative Effectiveness of Ultrasonography, 99mTc-Sestamibi, and 18F-Fluorocholine PET/CT in Detecting Parathyroid Adenomas in Patients With Primary Hyperparathyroidism. Clin. Nucl. Med. 2017, 42, e491–e497. [Google Scholar] [CrossRef] [PubMed]
  43. Hindié, E.; Zanotti-Fregonara, P.; Tabarin, A.; Rubello, D.; Morelec, I.; Wagner, T.; Henry, J.F.; Taïeb, D. The role of radionuclide imaging in the surgical management of primary hyperparathyroidism. J. Nucl. Med. 2015, 56, 737–744. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Alharbi, A.A.; Alshehri, F.M.; Albatly, A.A.; Sah, B.R.; Schmid, C.; Huber, G.F.; Huellner, M.W. [(18)F]Fluorocholine Uptake of Parathyroid Adenoma Is Correlated with Parathyroid Hormone Level. Mol. Imaging Biol. 2018, 20, 857–867. [Google Scholar] [CrossRef]
  45. Morland, D.; Lalire, P.; Deguelte, S.; Zalzali, M.; Richard, C.; Dejust, S.; Boulagnon, C.; Ly, S.; Papathanassiou, D.; Delemer, B. Added value of 18F-fluorocholine positron emission tomography-computed tomography in presurgical localization of hyperfunctioning parathyroid glands after dual tracer subtraction scintigraphy failure: A retrospective study of 47 patients. Medicine 2020, 99, e18681. [Google Scholar] [CrossRef]
  46. Yap, A.; Hope, T.A.; Graves, C.E.; Kluijfhout, W.; Shen, W.T.; Gosnell, J.E.; Sosa, J.A.; Roman, S.A.; Duh, Q.Y.; Suh, I. A cost-utility analysis of 18F-fluorocholine–positron emission tomography imaging for localizing primary hyperparathyroidism in the United States. Surgery 2022, 171, 55–62. [Google Scholar] [CrossRef]
Jcm 12 00812 g001 550
Figure 1. [18F]FCH PET/CT images (A–D) in a 67-year-old woman with elevated serum PTH of 102 pg/mL (normal value = 16–65) and calcium level of 2.67 mmol/l (normal value = 2.13–2.63), respectively. (A) Maximum intensity projection (MIP) shows an elongated focus of tracer uptake cranial to the right thyroid lobe (arrow). (B) transaxial PET (upper row) and hybrid PET/CT (lower row) images show focal tracer uptake posterior to the lower pole of the right thyroid lobe with SUV max of 8.3, mSAD = 5.5mm (arrows). Another mild focal uptake, posterior to the left thyroid upper-pole with SUVmax of 3.5 and mSAD = 3.5mm (arrowheads). (C) Coronal PET image shows two foci of small abnormal tracer uptake posterior to the upper poles of the thyroid (arrow and superior arrowhead) and one additional small faint uptake (inferior arrowhead) posterior to the lower pole of the left thyroid (SUVmax = 1.85 and mSAD = 2.68mm). (D) The corresponding coronal hybrid PET/CT image shows the exact localization of the detected lesions (arrows). The findings are suggestive of multiglandular parathyroid disease verified as three parathyroid adenomas on histopathology.
Figure 1. [18F]FCH PET/CT images (A–D) in a 67-year-old woman with elevated serum PTH of 102 pg/mL (normal value = 16–65) and calcium level of 2.67 mmol/l (normal value = 2.13–2.63), respectively. (A) Maximum intensity projection (MIP) shows an elongated focus of tracer uptake cranial to the right thyroid lobe (arrow). (B) transaxial PET (upper row) and hybrid PET/CT (lower row) images show focal tracer uptake posterior to the lower pole of the right thyroid lobe with SUV max of 8.3, mSAD = 5.5mm (arrows). Another mild focal uptake, posterior to the left thyroid upper-pole with SUVmax of 3.5 and mSAD = 3.5mm (arrowheads). (C) Coronal PET image shows two foci of small abnormal tracer uptake posterior to the upper poles of the thyroid (arrow and superior arrowhead) and one additional small faint uptake (inferior arrowhead) posterior to the lower pole of the left thyroid (SUVmax = 1.85 and mSAD = 2.68mm). (D) The corresponding coronal hybrid PET/CT image shows the exact localization of the detected lesions (arrows). The findings are suggestive of multiglandular parathyroid disease verified as three parathyroid adenomas on histopathology.
Jcm 12 00812 g001
Jcm 12 00812 g002 550
Figure 2. [18F]FCH PET/CT images (A–C) in a 62-year-old woman with elevated serum PTH of 190 pg/mL (normal value = 16–65) and calcium level of 2.89 mmol/l (normal value = 2.13–2.63), respectively. (A) Maximum intensity projection (MIP) shows focal tracer uptake in the right upper mediastinum (arrow). (B) transaxial PET (upper row) and hybrid PET/CT (lower row) as well as (C) sagittal hybrid PET/CT images show focal tracer uptake in the right upper mediastinal region, lateral to the truncus brachiocephalicus with SUVmax of 5.2 and mSAD = 11mm, compatible with an ectopic parathyroid adenoma (arrows), that was found to be 20mm ectopic parathyroid adenoma on histopathology result.
Figure 2. [18F]FCH PET/CT images (A–C) in a 62-year-old woman with elevated serum PTH of 190 pg/mL (normal value = 16–65) and calcium level of 2.89 mmol/l (normal value = 2.13–2.63), respectively. (A) Maximum intensity projection (MIP) shows focal tracer uptake in the right upper mediastinum (arrow). (B) transaxial PET (upper row) and hybrid PET/CT (lower row) as well as (C) sagittal hybrid PET/CT images show focal tracer uptake in the right upper mediastinal region, lateral to the truncus brachiocephalicus with SUVmax of 5.2 and mSAD = 11mm, compatible with an ectopic parathyroid adenoma (arrows), that was found to be 20mm ectopic parathyroid adenoma on histopathology result.
Jcm 12 00812 g002
Jcm 12 00812 g003 550
Figure 3. [18F]FCH PET/CT images (A,B) in a 53-year-old woman with elevated serum PTH of 73 pg/mL (normal value = 16–65) and calcium level of 2.70 mmol/L (normal value = 2.13–2.63), respectively. (A) Maximum intensity projection (MIP) shows focal tracer uptake in the cranial part of the left thyroid lobe (arrow). (B) Transaxial PET image (upper row) and hybrid PET/CT (lower row) images show focal tracer uptake posterior to the upper pole of the left thyroid lobe with SUVmax of 8.2 and mSAD = 8.2mm, which was found to be hyperplasia on histopathology result.
Figure 3. [18F]FCH PET/CT images (A,B) in a 53-year-old woman with elevated serum PTH of 73 pg/mL (normal value = 16–65) and calcium level of 2.70 mmol/L (normal value = 2.13–2.63), respectively. (A) Maximum intensity projection (MIP) shows focal tracer uptake in the cranial part of the left thyroid lobe (arrow). (B) Transaxial PET image (upper row) and hybrid PET/CT (lower row) images show focal tracer uptake posterior to the upper pole of the left thyroid lobe with SUVmax of 8.2 and mSAD = 8.2mm, which was found to be hyperplasia on histopathology result.
Jcm 12 00812 g003
Jcm 12 00812 g004 550
Figure 4. Drawn ROC curves for [18F]FCH PET/CT (AUC = 0.84) versus clinical ultrasonography (AUC = 0.57) diagnostic accuracies in detecting mild primary hyperparathyroidism.
Figure 4. Drawn ROC curves for [18F]FCH PET/CT (AUC = 0.84) versus clinical ultrasonography (AUC = 0.57) diagnostic accuracies in detecting mild primary hyperparathyroidism.
Jcm 12 00812 g004
Table
Table 1. Detailed characteristics of the patient’s population (n = 271).
Table 1. Detailed characteristics of the patient’s population (n = 271).
Mean ± SD|Number (%)
Patient DiagnosisoPHPTNCmPHPTNHmPHPT
Age66 ± 1368 ± 1362 ± 11
BMI27 ± 627 ± 526 ± 4
iPTH (pg/dL)159 ± 160135 ± 9658 ± 14
Calcium (mmol/L)2.8 ± 0.22.38 ± 0.272.74 ± 0.05
Phosphorus (mmol/dL)0.8 ± 0.20.83 ± 0.180.85 ± 0.23
Creatinine (mg/dL)1.2 ± 1.60.9 ± 0.31 ± 0.6
Alkaline phosphatase (U/I)88 ± 3776 ± 2774 ± 16
Female/Male225/46 (83%/17%)32/7 (82%/18%)7/4 (64%/36%)
History of thyroid disease172 (64%)26 (67%)7 (64%)
History of renal stone28 (10%)3 (8%) 1 (9%)
History of cholelithiasis18 (7%)2 (5%)1 (9%)
Surgery/Conservative200/71 (74%/26%)19/20 (49%/51%)4/7 (36%/64%)
Table
Table 2. Detailed laboratory results of the included patients.
Table 2. Detailed laboratory results of the included patients.
Initial PTH (pg/dL)Follow-Up PTH
(pg/dL)		Initial Calcium
(mmol/L)		Follow-up Calcium
(mmol/L)
True-PositiveOvert164 ± 17262 ± 582.78 ± 0.272.43 ± 0.33
Normocalcemic142 ± 10576 ± 572.36 ± 0.312.42 ± 0.15
Normohormonal62 ± 858 ± 63.11 ± 0.182.40 ± 0.22
True-NegativeOvert180 ± 22878 ± 472.79 ± 0.212.62 ± 0.17
Normocalcemic77 ± 642.75 ± 12.402.33 ± 0.062.42 ± 0.09
Normohormonal41 ± 2848 ± 242.91 ± 0.012.86 ± 0.02
False-PositiveOvert911032.712.56
Normocalcemic118 ± 21107 ± 182.50 ± 0.042.52 ± 0.30
Normohormonal----
False-NegativeOvert103 ± 1117 ± 0.72.72 ± 12.77 ± 1
Normocalcemic160 ± 81168 ± 1092.47 ± 0.032.51 ± 0.25
Normohormonal----
Data represented as mean values ± SD.
Table
Table 3. Correlation between the semi-quantitative parameters of the index lesions on [18F]FCH PET/CT and initial laboratory data.
Table 3. Correlation between the semi-quantitative parameters of the index lesions on [18F]FCH PET/CT and initial laboratory data.
[18F]FCH PET/CT ParametersOvert PHPTNormocalcemic mPHPTNormohormonal mPHPT
iPTH
(rp *, p-Value)		Calcium
(rp, p-Value)		iPTH
(rp, p-Value)		Calcium
(rp, p-Value)		iPTH
(rp, p-Value)		Calcium
(rp, p-Value)
SUVmax0.199, <0.010.163, <0.010.234, >0.1−0.353, <0.05−0.055, >0.1−0.699, <0.05
SUVmean0.214, <0.010.092, >0.10.364, <0.05−0.171, >0.1−0.090, >0.1−0.586, >0.05
SULpeak0.237, <0.0010.187, <0.010.299, >0.1−0.234, >0.1−0.017, >0.1−0.706, <0.05
SULmean0.190, <0.010.076, >0.10.305, >0.050.064, >0.1−0.105, >0.1−0.686, <0.05
mSAD (mm)0.218, <0.0010.134, <0.050.364, <0.05−0.201, >0.1−0.845, <0.01−0.360, >0.1
* Pearson’s r.
Table
Table 4. Detailed histopathology findings of the removed glands.
Table 4. Detailed histopathology findings of the removed glands.
Pathology
AdenomaHyperplasiaNormalSizeWeight
Overt PHPT2015817 ± 7 (mm)1.2 ± 1.7 (g)
Mild PHPT221014.4 ± 6.2 (mm)0.75 ± 0.8 (g)
Table
Table 5. Detailed patient-based findings of mPHP-cohort in [18F] FCH PET/CT and clinical ultrasonography (cUS) versus the reference standard.
Table 5. Detailed patient-based findings of mPHP-cohort in [18F] FCH PET/CT and clinical ultrasonography (cUS) versus the reference standard.
Reference StandardNCmPHP (n = 38)NHmPHP (n = 11)
FCH PET/CTcUSFCH PET/CTcUS
+−+−+−+−
Positive (+)29312209045
Negative (−)24150211
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Seyedinia, S.S.; Mirshahvalad, S.A.; Schweighofer-Zwink, G.; Hehenwarter, L.; Rendl, G.; Pirich, C.; Beheshti, M. Evolving Role of [18F]Flurocholine PET/CT in Assessing Primary Hyperparathyroidism: Can It Be Considered the First-Line Functional Imaging Approach? J. Clin. Med. 2023, 12, 812. https://doi.org/10.3390/jcm12030812

AMA Style

Seyedinia SS, Mirshahvalad SA, Schweighofer-Zwink G, Hehenwarter L, Rendl G, Pirich C, Beheshti M. Evolving Role of [18F]Flurocholine PET/CT in Assessing Primary Hyperparathyroidism: Can It Be Considered the First-Line Functional Imaging Approach? Journal of Clinical Medicine. 2023; 12(3):812. https://doi.org/10.3390/jcm12030812

Chicago/Turabian Style

Seyedinia, Seyedeh Sara, Seyed Ali Mirshahvalad, Gregor Schweighofer-Zwink, Lukas Hehenwarter, Gundula Rendl, Christian Pirich, and Mohsen Beheshti. 2023. "Evolving Role of [18F]Flurocholine PET/CT in Assessing Primary Hyperparathyroidism: Can It Be Considered the First-Line Functional Imaging Approach?" Journal of Clinical Medicine 12, no. 3: 812. https://doi.org/10.3390/jcm12030812

APA Style

Seyedinia, S. S., Mirshahvalad, S. A., Schweighofer-Zwink, G., Hehenwarter, L., Rendl, G., Pirich, C., & Beheshti, M. (2023). Evolving Role of [18F]Flurocholine PET/CT in Assessing Primary Hyperparathyroidism: Can It Be Considered the First-Line Functional Imaging Approach? Journal of Clinical Medicine, 12(3), 812. https://doi.org/10.3390/jcm12030812

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop